Quest Diagnostics 3 Giralda Farms
Madison
NJ 07940
USA
[t] 001 973 520 2900
|
|
|
| |
|
An agreement is forged between Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, and Surescripts, The Nation's E-Prescription Network, to form an integrated service to make laboratory and prescription information broadly and easily accessible to physicians. |
08 March 2010 |
| |
|
Quest Diagnostics is introducing the Care360 EHR (Electronic Health Record), which represents the next evolution of the company’s innovative Care360 platform used by the company's growing base of 150,000 connected physicians. |
05 March 2010 |
| |
|
A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the USA through Quest Diagnostics, the world's leading cancer diagnostics company. |
12 January 2010 |
| |
|
HemoCue signs an agreement with Medical Automation Systems (MAS) for the development of a RALS-Plus module for the HemoCue 201 DM analyser whole blood systems for haemoglobin and glucose point-of-care measurement. |
23 June 2009 |
| |
|
Quest Diagnostics introduces a new laboratory developed test designed to help physicians determine whether a patient with a history of HIV drug resistance will respond to the latest class of HIV antiretroviral therapies. |
15 June 2009 |
| |
|
A study in the June issue of Clinical Gastroenterology and Hepatology, published by Elsevier, demonstrates that the Hepascore liver fibrosis blood-serum test panel may help physicians more accurately diagnose and stage liver fibrosis in patients with chronic hepatitis C (HCV), potentially alleviating the need for liver biopsy, the standard of care for staging fibrosis, in a particular subset of patients. |
09 June 2009 |
| |
|
HemoCue, an international company in the field of point-of-care testing and a subsidiary of Quest Diagnostics, signs an agreement with MEC Dynamics (MEC) for the exclusive distribution of the Avie A1c point-of-care test in the USA and Europe. |
04 June 2009 |
| |
|
Quest Diagnostics launches the EGFR Pathway test (KRAS with reflex to NRAS, BRAF), the first laboratory-developed test from a national commercial reference laboratory for comprehensively identifying, in a single reflex test offering, genetic mutations in the KRAS, NRAS and BRAF genes. |
02 June 2009 |
| |
|
Quest Diagnostics is enabling patients and their physicians to share diagnostic laboratory test results, using Microsoft HealthVault. |
18 May 2009 |
| |
|
Quest Diagnostics' Focus Diagnostics infectious disease reference laboratory introduces a laboratory-developed real-time polymerase chain reaction (PCR) test to aid in identifying Influenza A H1N1 Swine-origin (H1N1) flu virus (S-OIV or novel H1N1), also known as the Swine Flu. |
13 May 2009 |
| |
|
Quest Diagnostics scientists provide new insights into genetic factors affecting the accuracy and quality of Cystic Fibrosis (CF) carrier and newborn screening in three separate articles to be published in the May 2009 issue of The Journal of Molecular Diagnostics. |
29 April 2009 |
| |
|
Quest Diagnostics’ ClariSure microarray-based comparative genomic hybridization (aCGH) postnatal test is now available for testing on patients in the state of New York in the USA. |
18 March 2009 |
| |
|
The Irish National Cancer Screening Service (NCSS) has selected Quest Diagnostics to provide quality-assured screening services intended to improve medical outcomes and reduce anxiety wait time for women ages 25 to 60 who participate in Ireland's first nationwide cytology-screening programme. |
23 June 2008 |
| |
|
Quest Diagnostics has released results of a study that demonstrates that a novel diagnostic testing technique is the first to provide direct, accurate and reproducible physical measurement of both the size and concentration of a broad range of lipoproteins in blood plasma. |
04 June 2008 |
| |
|
An analysis of a study presented at the 39th Annual Digestive Disease Week (DDW) Conference shows that among patients at increased risk for colorectal cancer who completed an annual faecal immunochemical (FIT) test, detection of cancerous lesions occurred an average of 26.5 months earlier than would have occurred during the three- or five-year study-required colonoscopy. |
21 May 2008 |
| |
|
Quest Diagnostics and Google Health have collaborated to provide patients and physicians with a new way to share diagnostic laboratory data online. |
20 May 2008 |
| |
|
Enterix , a wholly-owned subsidiary of Quest Diagnostics , has introduced the InSure Quik F I T faecal immunochemical test, a point-of-care version of the company's lab-based InSure FIT test, that provides physicians with the sensitivity and specificity of the laboratory-based InSure FIT test. |
09 May 2008 |
| |
|
Patients throughout the USA may soon have easy and secure access to their own medical diagnostic laboratory records as a result of a new collaboration between Quest Diagnostics and Google. |
03 March 2008 |
| |
| |
